SCHEMBL4868547

SCHEMBL4868547

COc1cc2ncnc(Nc3ccc(OCc4cccnc4)c(Cl)c3)c2cc1N

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.76
EPHA2 P29317 10/20 0.76
EPHB4 P54760 8/20 0.76
FLT1 P17948 1/20 0.76
EGFR P00533 9/20 0.64
GAK O14976 1/20 0.64
ERBB2 P04626 9/20 0.59
ERBB4 Q15303 1/20 0.54
RET P07949 1/20 0.52
KIF5B P33176 1/20 0.52
AURKA O14965 1/20 0.52
INSR P06213 1/20 0.52
FBP1 P09467 1/20 0.52
PDGFRB P09619 1/20 0.52
FLT4 P35916 1/20 0.52
CLK1 P49759 1/20 0.52
TEK Q02763 1/20 0.52
AURKB Q96GD4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6102556 0.92 KDR (0.67) KDREPHA2EPHB4FLT1EGFR
SCHEMBL9910688 0.90 EGFR (0.69) KDREPHA2EPHB4FLT1EGFR
SCHEMBL6103476 0.88 KDR (0.64) KDREPHA2EPHB4FLT1EGFR
SCHEMBL9910674 0.87 EGFR (0.71) KDREPHA2EPHB4FLT1EGFR
SCHEMBL906880 0.86 EPHA2 (1.00) KDREPHA2EPHB4FLT1EGFR
SCHEMBL4867054 0.86 KDR (0.65) KDREPHA2EPHB4FLT1EGFR
SCHEMBL9910672 0.86 EGFR (0.86) KDREPHA2EPHB4EGFRGAK
SCHEMBL4577785 0.85 EGFR (0.76) KDREPHA2EPHB4FLT1EGFR
SCHEMBL2255348 0.84 EGFR (0.69) KDREPHA2EPHB4EGFRGAK
SCHEMBL5125818 0.84 EGFR (0.60) KDREPHA2EPHB4FLT1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844022-B1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2013-08-14 EP claimed
JP-2008525522-A 2008-07-17 JP claimed
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof HANMI PHARM CO., LTD (KR) 2008-01-10 US claimed
EP-1844022-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-10-17 EP claimed
WO-2006071017-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO claimed
WO-2006071079-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO claimed
EP-1844022-B1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2013-08-14 EP disclosed
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof HANMI PHARM CO., LTD (KR) 2008-01-10 US disclosed
EP-1844022-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-10-17 EP disclosed
WO-2006071017-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO disclosed
WO-2006071079-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDR 2570/4885EPHA2 4530/4885EPHB4 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.